Bank of New York Mellon Corp boosted its position in Myovant Sciences Ltd (NASDAQ:MYOV) by 36.3% during the first quarter, Holdings Channel reports. The fund owned 23,784 shares of the company’s stock after buying an additional 6,330 shares during the period. Bank of New York Mellon Corp’s holdings in Myovant Sciences were worth $279,000 at the end of the most recent reporting period.

Separately, Wells Fargo & Company MN boosted its stake in shares of Myovant Sciences by 331.9% in the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock worth $194,000 after buying an additional 12,700 shares during the last quarter.

Myovant Sciences Ltd (MYOV) opened at 11.46 on Tuesday. Myovant Sciences Ltd has a 12 month low of $10.14 and a 12 month high of $15.50. The company’s 50-day moving average is $11.47 and its 200-day moving average is $11.82. The company’s market cap is $690.81 million.

ILLEGAL ACTIVITY NOTICE: “Bank of New York Mellon Corp Has $279,000 Stake in Myovant Sciences Ltd (NASDAQ:MYOV)” was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/08/bank-of-new-york-mellon-corp-has-279000-stake-in-myovant-sciences-ltd-nasdaqmyov.html.

Separately, Zacks Investment Research cut shares of Myovant Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $18.20.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Want to see what other hedge funds are holding MYOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myovant Sciences Ltd (NASDAQ:MYOV).

Institutional Ownership by Quarter for Myovant Sciences (NASDAQ:MYOV)

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.